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Tumor	volume	(mm3)	 =			 π 6 		 *	 			(a2	*	b)	 																																											(3.3)	
				
	Where	a	is	the	shortest	and	b	is	the	longest	transversal	diameter	of	the	tumor.	
	
Figure	3.2	Graphical	illustration	of	tumor	size	measurements.	
The	Figure	illustrates	the	location	and	shape	of	the	tumors	and	the	method	for	tumor	size	measurements.	
The	letter	“a”	represents	the	shortest	transversal	diameter	of	the	tumor,	while	the	letter	“b”	represents	
the	longest	transversal	diameter	of	the	tumor.	The	Figure	is	adapted	from	(Sortland,	2014)	with	
permission.	
	
3.4.2	Measurement	of	tumor	interstitial	fluid	pressure	
The	interstitial	fluid	pressure	(IFP)	in	the	tumors	was	measured	using	the	wick-in-
needle	technique.	In	this	technique,	a	fine	hypodermic	needle	(23	Gauge,	outer	diameter:	
0.6	mm)	provided	with	a	2-4	mm	long	side	hole	filled	with	nylon	floss	(wick)	and	saline	
was	inserted	into	the	central	part	of	the	tumors.	Through	a	PE-50	catheter	filled	with	
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saline,	the	wick-filled	needle	was	connected	to	a	fluid-filled	pressure	transducer	further	
connected	to	PowerLab	(PowerLab/8sp,	ADinstruments	Ltd.,	UK),	a	high-performance	
data	acquisition	system,	via	an	amplifier	(Bridge	Amp,	ADinstruments	Ltd.,	UK).	The	
pressure	data	was	converted	to	mmHg	on	a	computer	using	the	software	Chart5	for	
windows	(PowerLab/8sp	ADinstruments	Ltd.,	UK).	This	setup	enabled	continuous	and	
stable	recordings	of	the	interstitial	fluid	pressure.		
	
A	system	calibration	was	performed	before	each	pressure	measurement.	In	order	to	
calibrate	the	system,	a	water	column	filled	to	the	level	of	20	mmHg	was	connected	to	the	
transducer.	When	the	water	column	exerted	pressure	of	20	mmHg	on	the	transducer,	
the	electrical	output	signal	was	adjusted	to	20	mmHg	on	the	computer.	The	system	was	
thereafter	exposed	to	atmospheric	pressure	where	the	electrical	output	signal	was	
adjusted	to	0	mmHg.	The	system	calibrations	at	0	mmHg	and	20	mmHg	provided	the	
software	with	pressure	reference	values	and	enabling	accurate	pressure	measurements.	
	
Before	and	after	each	measurement,	a	zero	reference	pressure	was	obtained	by	placing	
the	needle	in	a	drop	of	saline	at	the	level	of	needle	insertion	site	in	the	tumor.	Only	
measurements	with	equal	(±	1	mmHg)	zero	pressure	reference	measurements	were	
accepted.			
	
During	each	pressure	measurement,	the	fluid	communication	between	the	needle	and	
the	transducer	was	confirmed	by	compression	and	decompression	of	the	catheter	
(clamping).	The	clamping	caused	a	transient	rise	and	fall	of	the	pressure,	and	only	
measurements	where	the	pressure	returned	to	the	pre-clamped	level	(±	1	mmHg)	was	
accepted.		
	
IFP	measurements	were	performed	earliest	4	hours	after	the	last	drug	administration.	
All	animals	were	anaesthetized	during	for	the	IFP	measurements	and	placed	on	a	
regulated	heating	pad	to	keep	their	body	temperature	at	38-39OC.	After	measurements,	
and	while	still	anaesthetized,	the	mice	were	sacrificed	by	cervical	dislocation	and	the	
tumors	were	excised	and	snap	frozen	in	liquid	nitrogen	or	fixated	in	4%	formalin	
(Thermo	scientific,	Rockford,	IL,	USA)	for	further	analysis.		
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3.4.3	Sectioning	of	frozen	tissue	samples	
The	tumor	tissue	intended	for	immunohistochemistry	were	snap	frozen	in	liquid	
nitrogen	after	excision	and	subsequently	sectioned	into	10	µm	sections	using	a	cryostat.		
	
Tissue-Tek	(4583,	Sakura	Finetek	Europe	B.V,	Netherlands)	was	applied	to	the	specimen	
disc	to	connect	the	frozen	tumor	tissue	to	the	specimen	disc.	The	tumor	tissue	was	then	
covered	in	Tissue-Tek	and	kept	at	-21oC	until	the	Tissue-Tek	was	frozen.	The	specimen	
disk	was	screwed	onto	the	specimen	head	of	the	cryostat	(Leica	CM3050	S	Cryostat,	
Leica	Biosystems,	Germany)	and	adjusted	so	that	the	knife	reached	the	specimen.	The	
tumor	tissue	was	cut	into	10	µm	sections	and	placed	onto	a	SuperFrost	plus	slide	
(Thermo	Scientific,	USA).	From	each	tumor	there	were	made	5	slides	with	3-4	tissue	
sections	on	each.	The	slides	were	stored	at	-80OC	until	further	use.		
	
3.4.4	Immunohistochemistry	staining	for	CD31	
The	general	principle	of	immunohistochemistry	is	the	demonstration	of	antigens	within	
tissue	sections	by	the	means	of	specific	antibodies	(Ramos-Vara,	2005).	CD31,	also	
known	as	platelet	endothelial	cell	adhesion	molecule-1	(PCAM-1)	is	a	130-kDa	
membrane-spanning	glycoprotein	expressed	in	platelets,	monocytes,	neutrophils,	
certain	T	lymphocytes	and	vascular	endothelial	cells	(Cicmil	et	al.,	2002).	CD31	is	
involved	in	angiogenesis,	thus	the	demonstration	of	its	presence	by	
immunohistochemistry	is	used	as	a	measure	of	the	degree	of	vascularisation.	The	
protocol	used	for	CD31	immunohistochemistry	staining	in	this	thesis	was	the	indirect	
method,	where	Rat	anti-Mouse	CD31	(MCA2388,	Bio-Rad,	UK)	is	used	as	primary	
antibody	and	biotinylated	Rabbit	anti-Rat	(PK-4004,	Vector	Laboratories,	Burlingame,	
CA,	USA)	is	used	as	secondary	antibody.		
	
Frozen	tissue	sections	(10	µm)	were	fixated	in	100-200	µL	ice-cold	acetone	(32201,	
Sigma-Aldrich,	Germany)	and	stored	at	-4OC	for	10	min.	Subsequently,	the	sections	were	
washed	3	times	for	5	min	in	phosphate	buffered	saline	(PBS)	(P3813,	Sigma	Life	Science,	
USA),	pH	7.4.	This	washing	procedure	was	repeated	between	each	step	unless	otherwise	
stated.	Any	endogenous	peroxidase	activity	was	blocked	by	30	min	incubation	in	a	
diluted	solution	(0.3%)	of	hydrogen	peroxidase	(Vnr.	803962,	Norges	Apotekerforening,	
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Ås	produksjonslab	AS)	in	methanol	(322415,	Sigma-Aldrich,	Germany).	Unspecific	
binding	of	the	primary	antibody	was	blocked	by	30	min	incubation	with	rabbit	serum	
(PK-4004,	Vector	Laboratories,	Burlingame,	CA,	USA)	diluted	1:40	in	PBS	with	0.3%	
Triton	X-100	(PBS-TX)	(T8787,	Sigma-Aldrich,	Germany),	pH	7.4.	Subsequently,	the	
tissue	sections	were	incubated	with	the	primary	antibody	Monoclonal	Rat	anti-Mouse	
CD31	(clone	ER-MP12,	MCA2388,	Bio-Rad,	UK)	diluted	1:200	in	PBS-TX	at	4OC	
overnight.		
	
The	following	day,	the	tissue	sections	were	washed	with	PBS	and	incubated	with	the	
secondary	antibody	Biotinylated	Polyclonal	Rabbit	anti-Rat	IgG	(PK-4004,	Vector	
Laboratories,	Burlingame,	CA,	USA)	diluted	1:200	in	PBS-TX	for	30	min.	While	
incubating,	the	avidin-biotin	complex	(ABC)	solution	was	prepared	(2	drops	of	Reagent	
A	in	10	mL	PBS-TX	were	mixed	followed	by	addition	and	mixing	of	2	drops	of	Reagent	B)	
and	left	in	room	temperature	for	30	min.		
	
After	incubation,	the	tissue	sections	were	washed,	first	with	PBS,	then	with	Tris	buffered	
saline	(TBS)	(R029,	G-Biosciences,	St.	Louis,	MO,	USA),	pH	7.5.	The	staining	solution	3.3`-
Diaminobenzidine	(DAB)	(ab64238,	abcam,	Cambridge,	UK),	which	yields	a	brown	color,	
was	then	prepared	by	diluting	DAB	Chromogen	1:50	in	DAB	substrate.	The	tissue	
sections	were	incubated	with	staining	solution	until	desired	stain	intensity	developed	
(approximately	2-4	min).	The	staining	reaction	was	quenched	by	addition	of	TBS	
followed	by	PBS	wash.	
	
To	achieve	a	coloration	contrast	between	the	tumor	tissue	and	the	blood	vessels,	the	
tissue	sections	were	counterstained	with	Richardson	stain.	Thereby	creating	a	contrast	
between	the	tissue,	stained	in	blue	with	Richardson,	and	the	target	antigens,	stained	in	
brown	with	DAB	(Figure	3.3).			
	
Counterstaining	was	performed	with	Richardson	stain	followed	by	washing	in	ddH2O	to	
remove	excess	staining	solution.	The	tissue	sections	were	subsequently	dehydrated	in	
increasing	concentrations	of	ethanol	(50%,	75%,	96%	and	100%)	(46139,	Sigma-
Aldrich,	Germany),	and	xylol	(95670,	Sigma-Aldrich,	Germany).	The	sections	were	
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mounted	with	histokitt		(1025/500,	Glaswarenfabrik	Karl	Hecht,	Germany)	and	
coverslipped.		
	
After	staining,	all	samples	were	examined	using	a	light	microscope	(Nikon	Eclipse	E600,	
724064;	Nikon,	Tokyo,	Japan)	connected	to	a	camera	(Nikon	Digital	Sight	DS-U3,	
250430;	Nikon,	Tokyo,	Japan)	and	a	computer	with	the	software	NIS	Element	3.2	64-bit.		
The	tissue	section	was	examined	in	a	100x	magnification	field	(i.e.,	10x	objective	lens	
and	10x	ocular	lens)	to	identify	microvessel	“hot	spots”	i.e.,	areas	with	high	
concentration	of	microvessels	in	the	tissue	section.	Five	to	seven	images	were	then	
captured	from	the	hot	spots	in	each	tumor	at	higher	magnification	(200x).	In	an	
organized	pattern,	the	CD31	positive	areas	were	quantified	manually	per	mm2,	and	the	
average	number	(vessels/mm2)	was	calculated.	An	optical	grid	was	added	to	each	image	
to	enhance	quantification.				
	
	
Figure	3.3.	Anti-CD31	stained	tissue	section	from	an	α11-KO	mouse.	
The	Figure	displays	a	representative	CD31	stained	tissue	section	from	an	α11-KO	mouse	in	the	Gleevec	
group.	The	blood	vessels	are	stained	in	brown	by	the	staining	solution	3.3`-Diaminobenzidine	(DAB),	
while	the	tissue	is	counterstained	in	blue	with	Richardson	stain.	The	scale	bar	represents	200	µm.	The	
image	was	captured	at	200x	magnification.			
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3.4.5	Picrosirius	red	staining	
Picrosirius	red	staining	is	a	commonly	used	method	for	visualizing	collagen	fibrils	in	
paraffin	embedded	tissue	sections.	Picrosirius	red	(F3BA)	is	a	strong,	linear	anionic	dye	
that	can	associate	along	cationic	collagen	fibres,	and	enhance	their	natural	birefringence	
under	cross-polarized	light	(Lattouf	et	al.,	2014).	Thus,	picrosirius	red	stained	collagen	
appears	red	in	light	microscopy	(Figure	3.4).		
	
The	tumor	tissue	intended	for	picrosirius	red	staining	were	fixated	in	4%	formalin	after	
excision	and	delivered	to	the	Molecular	Imaging	Center	(Department	of	Biomedicine,	
University	of	Bergen,	Norway)	for	paraffin	embedding	and	sectioning.	
	
The	paraffin-embedded	tissue	sections	(4	µm	thick)	were	deparaffinised	in	xylol	(95670,	
Sigma-Aldrich,	Germany)	and	an	ethanol	series	with	decreasing	concentration	(100%,	
96%	and	80%)(95670,	Sigma-Aldrich,	Germany).	Followed	by	hydration	under	running	
water	for	15	min	and	incubated	with	picrosirius	red	(24901B-250,	polysciences,	
Eppelheim,	Germany)	staining	solution	for	60	min.	After	incubation	the	tissue	section	
were	dehydrated	in	an	ethanol	series	with	increasing	concentrations	(80%,	96%	and	
100%)	and	xylol.	The	sections	were	then	mounted	with	histokitt		(1025/500,	
Glaswarenfabrik	Karl	Hecht,	Germany)	and	coverslipped.		
	
After	staining,	all	samples	were	examined	using	a	light	microscope	(Nikon	Eclipse	E600,	
724064;	Nikon,	Tokyo,	Japan)	connected	to	a	camera	(Nikon	Digital	Sight	DS-U3,	
250430;	Nikon,	Tokyo,	Japan)	and	a	computer	with	the	software	NIS	Element	3.2	64-bit.	
In	an	organized	pattern,	three	to	five	representative	images	were	captured	at	200x	
magnification	from	each	tissue	section.	The	images	were	analysed	with	the	National	
Institute	of	Health	ImageJ	software,	version	1.51s.	The	collagen	density	was	manually	
quantified	using	RGB	conversion	and	the	colour	threshold	tool,	the	collagen	content	was	
quantified	based	on	the	picrosirius	red	positive	area	(expressed	as	pixels)	of	each	image,	
and	expressed	as	the	percentage	of	picrosirius	red	positive	pixels,	according	to	Equation	
(3.4):	
	
%	Picrosirius	red	positive	pixels	=	
!"#$%$&' !"#! ∗!""%
(!"#$% !"#!!!"#$%&$'( !"#!)
																																												(3.4)	
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Where	the	positive	are	is	the	amount	of	pixels	positive	for	picrosirius	red,	the	total	area	
is	the	total	amount	of	pixels	in	the	image	and	the	deviating	area	is	the	parts	(pixels)	of	
the	image	not	suitable	for	quantification,	such	as	the	tumor	edge	or	necrotic	tissue.		
	
	
	
Figure	3.4.	Picrosirius	red	stained	tissue	section	from	a	WT	control	mouse.	
The	Figure	displays	a	representative	picrosirius	red	stained	tissue	section	from	a	wild	type	mouse	in	the	
control	group.	The	collagen	fibrils	are	shown	as	red	threads.	The	scale	bar	represents	100	µm.	The	image	
was	captured	at	200x	magnification.		
	
3.4.6	Statistics	
Statistical	analyses	were	performed	in	order	to	evaluate	differences	between	the	groups,	
and	identify	the	significance	of	these	findings.	For	statistical	analysis,	GraphPad	Prism	7	
(GraphPad	Software,	Inc.,	La	Jolla,	CA,	USA)	was	used.	One-way	ANOVA	with	Sidak´s	
multiple	comparisons	test	was	used	to	analyse	statistical	differences	between	the	
groups.	Results	were	accepted	as	statistical	significant	when	p	<	0.05.	The	data	is	given	
as	mean	±	standard	error	of	mean	(SEM)	and	the	number	of	measurements	(n)	refers	to	
number	of	tumors.			
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4	Results	
	
	
4.1	Genotyping	
The	integrin	α11	status	of	all	mice	used	in	this	thesis	was	confirmed	by	genotyping.	An	
earpiece	was	cut	from	each	mouse	and	genotyped	to	verify	that	they	were	either	α11	KO	
or	α11	WT.	Heterozygote	mice	were	used	for	further	breeding	to	produce	α11	KO	or	
α11	WT	offspring.		
	
	
	
Figure	4.1	Genotyping	
The	figure	displays	a	representative	image	of	genotyped	earpieces	from	mice	in	this	study.	Controls	are	
loaded	in	well	6-9,	containing	samples	from	verified	α11	KO,	heterozygote	(HZ),	α11	WT,	and	water,	
respectively.	Based	on	the	bands	from	the	controls,	the	samples	in	well	1-5	are	HZ,	WT,	WT,	KO,	and	HZ,	
respectively.		
	
	
4.2	Tumor	growth	
The	size	of	the	E0771	mammary	tumors	was	measured	at	day	1	and	again	at	day	4	of	the	
experiment,	using	a	caliper.	The	tumor	growth	(Figure	4.2)	was	determined	as	the	
average	increase	in	tumor	size	for	all	tumors	in	each	group	over	this	four-day	period.		
	
The	results	showed	no	statistical	significant	difference	in	tumor	growth	between	the	WT	
control	group	and	the	KO	control	group,	although	there	is	a	trend	towards	a	slight	
reduction	in	tumor	growth	in	the	integrin	α11-deficient	groups	compared	WT	control.		
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No	significant	difference	in	tumor	growth	was	found	between	the	WT	control	and	the	
WT	Gleevec	group	either,	indicating	no	effect	of	Gleevec	per	se	on	tumor	growth.		
	
Thus,	over	this	four-day	period,	no	influence	of	integrin	α11-deficiency	or	PDGFR-
inhibition	on	tumor	growth	was	seen.	However,	the	tumor	growth	was	significantly	
reduced	(p	=	0.029),	in	the	α11-deficient	KO	control	group	when	compared	to	the	WT	
Gleevec	group,	possibly	indicating	that	integrin	α11β1	has	higher	impact	on	tumor	
growth	than	PDGF	signalling	in	these	tumor	cells.		
			
	
Figure	4.2	Tumor	growth.	
The	columns	represent	the	growth	(mm3)	of	the	E0771	tumors	in	WT	control	(n=13),	KO	control	(n=12),	
WT	Gleevec	(n=16),	and	KO	Gleevec	(n=14)	mice.	The	tumor	growth	was	calculated	as	the	average	
increase	in	tumor	size	for	all	tumors	in	each	group	over	a	period	of	four	days.	The	values	are	given	as	
Means	±	SEM.	*	p	<	0.05.		
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4.3	Tumor	interstitial	fluid	pressure	
The	tumor	interstitial	fluid	pressure	(IFP)	was	determined	using	the	wick-in-needle	
technique,	as	described	in	section	3.4.2.	The	measurements	showed	significantly	lower	
IFP	in	all	groups	when	compared	to	the	WT	control	group,	as	shown	in	Figure	4.3.		
	
The	IFP	was	significantly	reduced	in	the	α11-deficient	KO	control	group	(p	=	0.002),	the	
WT	Gleevec	group	(p	=	0.047)	and	the	KO	Gleevec	group	(p	=	0.013),	suggesting	that	
both	integrin	α11β1	and	PDGF	signalling	affects	IFP	to	a	similar	extent	in	these	tumor	
cells.	However,	the	IFP	could	not	be	further	supressed	by	Gleevec	in	the	α11-deficient	
KO	Gleevec	group.		
	
	
Figure	4.3	Tumor	interstitial	fluid	pressure.		
The	columns	represent	the	tumor	interstitial	fluid	pressures	(mmHg)	of	the	E0771	tumors	in	WT	control	
(n=13),	KO	control	(n=12),	WT	Gleevec	(n=16),	and	KO	Gleevec	(n=14)	mice.	The	tumor	IFP	was	
calculated	as	the	average	IFP	for	all	tumors	in	each	group.	The	values	are	given	as	Means	±	SEM.	*	p	<	0.05,	
**	p	<	0.01	compared	to	WT	control.		
WT
 C
on
tro
l
KO
 C
on
tro
l
WT
 G
lee
ve
c
KO
 G
lee
ve
c
0
5
10
15
20
IF
P 
(m
m
H
g)
*
*
**
	 43	
4.4	Tumor	blood	vessel	density	
Immunohistochemical	anti-CD31	staining	was	used	to	quantify	the	blood	vessel	density	
in	the	tumor	tissue	sections.	For	each	tumor,	five	to	seven	representative	images	from	
the	viable	zone	(Figure	4.4)	were	captured	and	the	amount	of	blood	vessel	i.e.	the	
microvessel	density	(MVD)	was	manually	quantified	according	to	the	amount	of	anti-
CD31	stained	blood	vessels	per	mm2,	as	described	in	section	3.4.4.			
	
	
Figure	4.4	Anti-CD31	immunohistochemically	stained	tissue	sections.	
The	Figure	displays	representative	images	from	the	analysis	of	tumor	blood	vessel	density	in	anti-CD31	
immunohistochemically	stained	tissue	sections	from	the	WT	control	group	(A),	the	KO	control	group	(B),	
the	WT	Gleevec	group	(C),	and	the	KO	Gleevec	group	(D).	The	blood	vessels	are	stained	in	brown	by	the	
staining	solution	3.3`-Diaminobenzidine	(DAB),	while	the	tissue	is	counterstained	in	blue	with	Richardson	
stain.	The	scale	bar	on	the	optical	grid	in	the	centre	of	the	images	indicates	grid	size	of	100	µm,	and	the	
scale	bar	in	the	lower	left	hand	corner	in	each	image	indicates	200	µm.	The	images	were	captured	at	200x	
magnification.				
	
	
	
A B
C D
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The	quantification	of	the	anti-CD31	staining	showed	significant	reductions	(p	<	0.0001)	
in	the	MVD	in	all	groups	when	compared	to	the	WT	control	group,	as	shown	in	Figure	
4.5.	However,	the	α11-deficient	KO	control	group	had	significantly	lower	MVD	(p	<	
0.0001)	compared	to	the	Gleevec	groups	(WT	Gleevec	and	KO	Gleevec).	This	may	
indicating	that	angiogenesis	is	more	dependent	on	integrin	α11β1	than	PDGF	signalling	
in	these	tumor	cells.	Furthermore,	the	results	also	indicate	that	the	inhibitory	effect	seen	
in	the	α11-deficient	KO	control	group	is	partially	lost	in	the	α11-deficient	KO	Gleevec	
group.		
	
	
Figure	4.5	Tumor	blood	vessel	density.		
The	columns	represent	the	tumor	blood	vessel	densities	(blood	vessel	density	/	mm2)	in	tissue	sections	
from	WT	control	(n=6),	KO	control	(n=6),	WT	Gleevec	(n=5),	and	KO	Gleevec	(n=6)	mice.	The	tumor	blood	
vessel	density	was	calculated	as	the	average	for	all	tumors	sections	in	each	group.	The	values	are	given	as	
Means	±	SEM.	****	p	<	0.0001.		
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4.5	Tumor	collagen	density		
Picrosirius-red	staining	was	used	to	quantify	the	most	abundant	collagens,	type	I	and	
type	III,	in	the	tumor	sections.	For	each	tumor,	three	to	five	representative	images	
(Figure	4.6)	were	captured	to	evaluate	the	tumor	collagen	density.			
	
	
Figure	4.6	Picrosirius	red	stained	tissue	sections.	
The	Figure	displays	representative	images	from	the	analysis	of	tumor	collagen	density	in	picrosirius	red	
stained	tissue	sections	from	the	WT	control	group	(A),	the	KO	control	group	(B),	the	WT	Gleevec	group	
(C),	and	the	KO	Gleevec	group	(D).	The	scale	bar	in	the	lower	left	hand	corner	in	each	image	indicates	100	
µm.	The	images	were	captured	at	200x	magnification.					
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The	collagen	density	was	determined	using	the	ImageJ	software	and	quantified	
according	Equation	(3.4),	as	described	in	section	3.4.5.	The	collagen	quantification	
showed	(Figure	4.7)	a	significant	reduction	in	tumor	collagen	density	in	the	KO	control	
group	(p	<	0.0001),	when	compared	to	the	WT	control	group.		
	
No	significant	difference	in	collagen	density	was	observed	in	the	WT	Gleevec	group	
when	compared	to	the	WT	control	group,	or	in	the	α11-deficient	KO	Gleevec	group	
when	compared	to	the	KO	control	group.	Suggesting	that	the	PDGFR-inhibitor	Gleevec	
had	no	significant	effect	on	the	tumor	collagen	density	in	these	tumors.	
	
The	collagen	density	in	the	α11-deficient	groups,	KO	control	(p	=	0.0002)	and	KO	
Gleevec	(p	<	0.0001),	was	also	found	to	be	significantly	lower	when	compared	to	the	WT	
Gleevec	group.	Indicating	the	importance	of	integrin	α11β1	on	the	tumor	collagen	
density.			
	
Figure	4.7	Tumor	collagen	density.	
The	columns	represent	the	tumor	collagen	density	(%	picrosirius-red	positive	pixels)	in	WT	control	(n=4),	
KO	control	(n=3),	WT	Gleevec	(n=4),	and	KO	Gleevec	(n=4)	mice.	The	tumor	collagen	density	was	
calculated	as	the	average	for	all	tumors	sections	in	each	group.	The	values	are	given	as	Means	±	SEM.	***	p	
=	0.0002	and	****	p	<	0.0001.		
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5	Discussion	
	
The	discussion	section	is	sub-divided	into	three	sections.	The	first	section	consists	of	a	
discussion	of	the	methodological	aspects	of	this	thesis,	mainly	the	strengths	and	
potential	weaknesses	of	the	applied	methods.	The	following	sections	will	provide	a	
general	discussion	of	the	results	and	a	conclusion.			
	
5.1	Methodological	aspects	
	
5.1.1	Cell	line	and	growth	conditions	
The	objectives	of	this	thesis	were	to	study	the	in	vivo	effect	of	integrin	α11	and	PDGFR-
inhibition	in	triple-negative	breast	cancer,	thus	the	cell	line	needed	to	meet	certain	
criteria.	First,	it	needed	to	be	of	the	TNBC	phenotype.	Secondly,	it	needed	to	have	high	
take	rate	and	readily	grow	in	the	α11-KO	mouse	strain.	Lastly,	it	needed	to	express	
receptor	tyrosine	kinases,	such	as	PDGFR-β.						
	
The	murine	E0771	breast	cancer	cell	line	used	in	this	thesis,	is	an	aggressive	cell	line	
with	a	TNBC	phenotype	developed	on	the	C57BL/6	background	(VanGundy	et	al.,	2014;	
Johnstone	et	al.,	2015).	These	cells	readily	induce	tumors	in	mice	on	the	C57BL/6	
background,	such	as	the	α11-KO	mouse	strain	used	in	this	thesis	(see	section	5.1.2).	In	
addition,	a	previous	study	conducted	in	our	lab	has	demonstrated	that	the	receptor	
tyrosine	kinase	PDGFR-β	is	expressed	in	E0771	tumor	cells	(Figure	5.1).					
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Figure	5.1	PDGFR-β 	expression	in	the	E0771	murine	breast	cancer	cell	line	
The	western	blott	depicted	in	this	Figure	is	a	result	of	a	previous	study	from	our	lab	and	demonstrates	the	
expression	of	PDGFR-β	in	murine	E0771	tumor	cells.	The	expression	of	PDGFR-β	was	not	found	in	tumor	
cells	of	the	TNBC	murine	cell	line	4T1.	The	Figure	was	provided	by	Linda	Stuhr.			
	
	
The	E0771	cells	were	cultured	according	to	the	growth	conditions	recommended	by	the	
distributer	CH3BioSystems	(940001,	CH3BioSystems,	New	York,	USA).	These	growth	
conditions	are	also	supported	by	literature	(Ewens	et	al.,	2005;	Jia	et	al.,	2014).		
	
	
5.1.2	Animal	model	
Mice	has	long	served	as	the	preferred	animal	models	in	biomedical	research	due	to	their	
anatomical,	physiological,	and	genetic	similarity	to	humans	(Bryda,	2013).	After	the	
human	genome	was	sequenced	in	2001,	the	mouse	genome	followed	in	2002.	Thus,	
providing	a	wealth	of	genetic	information	on	the	species.	The	use	of	mice	for	research	
purposes	also	has	other	advantages,	the	small	size	and	generally	mild	temperament	
makes	them	easy	to	handle,	house	and	maintain.	In	addition,	mice	breed	efficiently	with	
short	gestation	time	and	relatively	large	numbers	of	offspring.	Mice	also	have	a	fairly	
rapid	development	to	adulthood.		
	
In	this	thesis,	the	integrin	α11-deficient	heterozygous	BALB/c	SCID	strain	was	used.	
This	mouse	strain	is	derived	from	the	C57BL/6	strain,	which	enhances	the	take	rate	and	
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induction	of	disease	with	the	C57BL/6	derived	E0771	cell	line	(VanGundy	et	al.,	2014;	
Navab	et	al.,	2016).	The	mice	were	bred	heterozygously,	and	the	integrin	α11	wild	type	
and	integrin	α11-deficient	offspring	were	used	in	the	experiments.	All	animal	breeding	
was	organized	and	performed	by	the	technical	staff	at	the	animal	facility	at	the	
Department	of	Biomedicine,	University	of	Bergen,	Norway.	All	mice	used	in	this	study	
were	genotyped	and	verified	as	α11	WT	or	α11	KO	by	polymerase	chain	reaction.	
	
	
5.1.3	Anaesthesia	
The	animals	were	subjected	to	anaesthesia	to	provide	a	minimum	of	stress	and	pain	
during	the	experimental	procedures.	The	method	of	anaesthesia	in	this	thesis	was	gas-
anaesthesia,	using	isoflurane	in	conjunction	with	oxygen	and	nitrous	oxide.		
	
Isoflurane	is	the	most	commonly	used	volatile	anaesthetic	for	experimental	
interventions	in	mice,	due	to	several	advantages	(Constantinides	and	Murphy,	2016).	
Both	the	induction	and	recovery	time	from	isoflurane	proceeds	quickly,	within	1-2	min	
(Cesarovic	et	al.,	2010).	The	reason	for	isofluranes	rapid	induction	and	recovery	times,	is	
explained	by	its	blood/gas	partition	coefficient,	i.e.	its	solubility	in	the	blood	(Dohoo,	
1990;	Sawyer,	2008,	pp.	156-164).	The	blood/gas	partition	coefficient	describes	the	
relative	affinity	of	an	inhalation	anaesthetic	for	the	fluid	(blood)	phase	and	the	gas	
(alveolar)	phase.	Isoflurane	has	a	blood/gas	partition	coefficient	of	1.4	at	37OC,	meaning	
that	at	equilibrium	the	concentration	of	isoflurane	in	the	blood	is	1.4	times	of	the	
concentration	in	the	gas	phase.	Inhalation	anaesthetics	with	relatively	low	solubility	in	
the	blood,	such	as	isoflurane,	will	quickly	increase	the	alveolar	concentrations	and	cause	
rapid	anaesthetic	induction,	and	recovery	through	pulmonary	ventilation	(Sawyer,	
2008,	pp.	156-164).		
	
Another	factor	that	contribute	to	isofluranes	rapid	uptake	into	and	elimination	from	the	
body,	is	its	high	vapour	pressure	(239.5	mmHg	at	20OC)	(Dohoo,	1990).	A	high	vapour	
pressure	means	that	anaesthetizing	concentrations	can	be	rapidly	attained,	thus	
decreasing	the	time	for	anaesthetic	induction.	However,	this	also	means	that	fatal	
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concentrations	may	be	rapidly	attained	as	well,	thus	care	has	to	be	taken	during	the	
anaesthetic	procedure.			
	
Isoflurane	is	a	potent	cerebral,	coronary	and	peripheral	vascular	vasodilator	
(Constantinides	and	Murphy,	2016).	However,	N2O	acts	as	a	balancing	agent	by	
antagonizing	isoflurane-induced	vascular	vasodilatory	responses	and	thus	stabilizing	
the	physiological	status	of	the	mice	(Constantinides	et	al.,	2011).	In	fact,	the	
supplemental	use	of	N2O	with	isoflurane	is	associated	with	higher	and	more	stable	
values	of	mean	arterial	pressure	(MAP)	and	heart	rate,	including	their	beat-to-beat	
variability	(Constantinides	and	Murphy,	2016).		
	
The	core	body	temperature	falls	during	any	kind	of	anaesthesia	(Cesarovic	et	al.,	2010).	
However,	due	to	the	small	size	and	high	body	surface	area	of	mice,	they	are	especially	
sensitive	to	hypothermia.	As	thermoregulation	is	vital	for	maintenance	of	homeostasis	
in	mice,	a	hot	plate	set	at	37OC	was	used	to	maintain	optimal	body	temperature	during	
experimental	procedures.		
	
	
5.1.4	Tumor	growth	
In	this	thesis,	tumor	size	was	measured	externally	using	a	caliper.	The	measurements	
were	collected	along	the	longest	two	dimensions	of	the	tumor	x/y	plane	and	the	z-axis	
dimension	was	assumed	equal	to	the	shortest	dimension.	The	tumor	volume	was	
calculated	with	the	assumption	of	elliptical	shape	according	to	Equation	3.3	(Tumor	
volume	=	π/6	x	a2	x	b),	where	“a”	represents	the	shortest	transversal	diameter	and	“b”	
represents	the	longest	transversal	diameter.	The	tumor	growth	was	calculated	as	the	
post-treatment	tumor	volume	minus	the	pre-treatment	tumor	volume.		
	
Measurements	of	xenograft	tumors	with	calipers	are	rapid,	non-invasive	and	
inexpensive.	However,	caliper	measurements	are	affected	by	contributions	from	
epidermis,	adipose	tissue	and	fur,	each	of	which	introduces	error	and	variability	into	the	
volume	determination	(Ayers	et	al.,	2010).	In	order	to	reduce	these	errors	to	a	
minimum,	the	fur	surrounding	the	tumors	were	shaved	off	and	the	tumor	shape	was	
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drawn	to	obtain	measurements	in	the	exact	same	orientation	for	both	measurement	
days	(day	1	and	4).	Each	tumor	was	also	measure	by	the	same	person,	as	the	intra-
individual	variability	during	measurements	was	assumed	to	be	less	then	the	inter-
individual	difference.	In	addition,	all	animals	were	anaesthetized	during	tumor	
measurements	to	improve	quality	of	the	measurements	as	well	as	alleviating	the	
animals	of	unnecessary	stress	and	discomfort.							
	
There	are	a	number	of	methods	in	which	more	precise	measurements	of	xenograft	
tumors	may	be	obtained,	such	as	computed	tomography	(CT),	magnetic	resonance	
imaging	(MRI)	and	bioluminescence	imaging	(BLI).	However,	these	methods	are	both	
time	consuming	and	expensive	(Ayers	et	al.,	2010).	Ultrasound	on	the	other	hand,	is	an	
inexpensive	and	non-invasive	method	for	measuring	xenograft	tumor	volume.	In	a	study	
by	Ayers	and	colleagues	in	2010	(Ayers	et	al.,	2010),	they	compared	the	accuracy	of	
volume	measurements	on	xenograft	tumors	using	ultrasound	imaging	and	external	
caliper.	Ayers	and	colleagues	found	that	caliper	volume	variance	was	1.3-fold	higher	
then	with	ultrasound.	Concluding	that	ultrasound	imaging	more	accurately,	and	
reproducibly	reflected	the	true	tumor	volume.	However,	ultrasound	imaging	requires	
time-consuming	training	and	was	not	available	at	the	institute,	and	therefore	not	
considered	as	an	option	in	this	project.			
	
	
5.1.5	Tumor	interstitial	fluid	pressure	
The	measurements	of	the	tumor	interstitial	fluid	pressure	were	conducted	using	the	
well-established	wick-in-needle	(WIN)	technique,	as	described	in	section	3.4.2.	The	WIN	
technique	was	developed	by	Fadnes	and	colleagues	in	the	late	1970s	(Fadnes	et	al.,	
1977),	in	an	attempt	to	combine	desirable	features	from	the	needle	method	and	the	wick	
catheter	technique	(Wiig	et	al.,	1986).	The	WIN	technique	combines	the	large	contact	
area	from	the	wick	catheter	technique	with	the	reasonably	atraumatic	insertion	
approach	of	the	needle	method,	using	a	thin	hypodermic	needle	(Wiig	et	al.,	1986;	
Pusenjak	and	Miklavcic,	1997).	Through	the	combination	of	these	features	and	
fulfilment	of	the	criteria	described	in	section	3.4.2,	the	WIN	technique	offers	a	simple	
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and	convenient	way	to	procure	reliable	and	reproducible	IFP	measurements	in	
experimentally	induced	tumors	in	animals	(Wiig	and	Swartz,	2012).			
5.1.6	Immunohistochemistry		
Immunohistochemistry	is	a	widely	used	method	to	visualise	the	distribution	and	
amount	of	certain	molecules	in	tissue	by	the	means	of	specific	antigen-antibody	
reactions	(Kim	et	al.,	2016).	In	this	thesis,	immunohistochemistry	was	used	to	determine	
the	degree	of	angiogenesis	in	the	tissue	sections,	a	commonly	used	surrogate	marker	of	
angiogenesis	is	the	MVD,	i.e.	the	number	of	vessels	counted	in	a	given	area	of	tissue	
(Goddard	et	al.,	2001).	In	order	to	visualize	and	quantify	the	MVD,	tumor	sections	was	
immunohistochemically	stained	for	the	pan-endothelial	marker	CD31	(Marien	et	al.,	
2016).		
	
5.1.6.1	Immunohistochemical	procedure	
The	immunohistochemical	anti-CD31	staining	technique	used	in	this	thesis	was	the	
indirect	method.	This	method	can	be	divided	into	four	main	steps.	Step	1	includes	all	
pre-immunologic	procedures,	such	as	fixation,	blocking	endogenous	activities	and	
blocking	nonspecific	bindings	(Ramos-Vara	et	al.,	2008).	Step	2	includes	all	immunologic	
reactions	between	the	primary	antibody	and	the	tissue	antigens,	the	reactions	between	
the	primary	and	the	secondary	antibody,	and	the	necessary	chemical	reactions	to	bind	
the	reporter	molecules.	Step	3	includes	all	procedures	necessary	for	visualization	of	the	
antigen-antibody	binding.	Step	4	includes	the	analysis	of	the	results.		
	
Step	1.	Pre-immunologic	procedures.	
The	tissue	sections	were	fixated	in	ice-cold	acetone.	This	type	of	fixation	is	known	as	
coagulative	fixation	(Ramos-Vara	et	al.,	2008).	Acetone	dehydrates	the	tissue	sections.	
By	removing	and	replacing	free	water,	acetone	destabilizes	hydrophobic	and	hydrophilic	
interactions.	This	disrupts	the	proteins	tertiary	structure	and	alters	their	physical	
properties,	which	causes	proteins	that	normally	are	soluble	in	aqueous	solutions	to	
become	insoluble.	In	this	way	coagulative	fixation	maintains	the	tissue	structure	and	
prevents	antigen	diffusion.		
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Endogenous	peroxidase	activity	can	react	with	the	staining	solution	DAB	to	produce	a	
brown	product,	which	is	indistinguishable	from	the	specific	immunostaining	(Ramos-
Vara,	2005).	This	was	avoided	by	pre-treatment	of	the	tissue	sections	with	a	diluted	
solution	of	hydrogen	peroxidase	in	methanol.		
	
Protein	blocking	may	reduce	unwanted	background	staining,	although	antibodies	have	
high	affinity	for	the	specific	target	antigen,	partial	or	weak	binding	to	non-specific	sites	
on	non-antigen	proteins	may	occur	(Kim	et	al.,	2016;	thermofisher.com,	2018).	This	
nonspecific	binding	may	cause	high	background	staining	that	can	interfere	with	the	
detection	of	the	target	antigen.		
	
Step	2.	Immunologic	procedures.	
The	indirect	immunochemistry	method	is	often	referred	to	as	the	two-step	indirect	
method,	as	it	consists	of	two	separate	layers	of	antibodies.	The	first	layer	is	usually	a	
highly	specific	unlabelled	monoclonal	antibody	for	the	target	antigen	(Ramos-Vara,	
2005).	The	second	layer	is	usually	a	labelled	polyclonal	antibody	that	is	raised	against	
the	primary	antibody.	This	method	was	developed	by	Coons	and	colleagues	(Coons	et	al.,	
1955)	in	order	to	meet	the	increasing	demand	for	a	more	sensitive	method.		
	
As	mentioned,	antibodies	can	either	be	monoclonal	or	polyclonal.	Monoclonal	antibodies	
are	obtained	from	a	single	clone	of	hybridoma,	which	produce	antibodies	(Kim	et	al.,	
2016).	Monoclonal	antibodies	are	highly	specific	and	only	bind	to	a	single	epitope	on	an	
antigen.	However,	the	possibility	of	cross-reactions	with	other	antigens	is	not	
eliminated,	as	the	amino	acid	sequence	of	the	target	epitope	may	exist	in	other	proteins	
(Ramos-Vara	and	Miller,	2014).	Polyclonal	antibodies	are	obtained	from	experimental	
animals	through	repetitive	stimulations	of	antigen	(Kim	et	al.,	2016).	These	antibodies	
are	less	specific	then	the	monoclonal	antibodies	and	has	affinity	for	a	broader	range	of	
antigens,	which	may	cause	greater	nonspecific	background	staining	(Ramos-Vara	et	al.,	
2008).	Polyclonal	antibodies	may	also	affect	the	reproducibility	due	to	batch	variability	
(Kim	et	al.,	2016).			
	
Both	the	primary	and	the	secondary	antibody	used	in	this	thesis	are	well-known	
antibodies	with	high	quality	literature	evidence.	In	addition,	our	lab	has	experience	with	
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the	use	of	these	particular	antibodies	in	mice	and	has	established	a	working	protocol	for	
their	use	in	immunohistochemical	anti-CD31	staining.		
	
The	detection	of	the	immune	reaction	mostly	depends	on	the	detection	system.	This	
system	needs	to	have	high	sensitivity	and	accuracy,	be	reproducible	and	render	a	high	
signal-to-noise	ratio	(Ramos-Vara	and	Miller,	2014).	The	ABC	method	is	one	of	the	most	
common	avidin-biotin	methods.	In	this	method,	HRP	conjugated	biotin	is	utilized	as	the	
reporter	molecule	and	avidin	as	a	linker,	connecting	the	HRP	conjugated	biotin	to	the	
biotinylated	secondary	antibody.	Avidin	is	a	glycoprotein	composed	of	four	identical	
subunits,	each	with	a	binding	site	for	biotin,	thereby	capable	of	binding	several	reporter	
molecules	to	each	biotinylated	antibody	(Ramos-Vara,	2005).	However,	avidin	may	
produce	high	background	by	binding	lectins	or	negatively	charged	tissue	components	
through	its	carbohydrate	groups	or	through	electrostatic	interactions	due	to	its	high	
isoelectric	point	(pI	∼	10).	
	
Step	3.	Visualization.	
The	visualization	of	the	antigens	was	enabled	by	addition	of	DAB,	a	common	staining	
agent	in	immunohistochemistry.	The	enzyme	HRP	oxidizes	and	converts	DAB	to	an	
insoluble	polymer,	which	precipitates	as	a	dark	brown	pigment	at	the	reaction	sites	
allowing	visualization	of	the	target	antigens	(Dölle	et	al.,	2018).					
	
In	order	to	reduce	visual	misinterpretations	of	the	immunologic	reaction,	the	tissue	
sections	were	counterstained	with	Richardson´s	stain.	This	staining	method	produces	a	
blue	colour,	which	eases	the	visual	differentiation	of	the	target	antigens	in	the	tissue	
sections.		
	
Step	4.	Analysis.	
The	intratumoral	microvessel	density	was	determined	manually	using	the	variant	of	
Weidner	approach	(Weidner	et	al.,	1991).	The	tissue	section	was	first	scanned	using	a	
light	microscope	at	low	magnification	to	identify	the	areas	with	the	highest	microvessel	
density	(the	vascular	hot	spots)	in	the	tumor	periphery.	Five	to	ten	of	these	vascular	hot	
spots	were	selected	from	each	tumor.	The	microvessels	were	manually	counted	under	
higher	magnification	(200x),	as	described	in	section	3.4.4.	An	optical	grid	(100	µm)	was	
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used	to	aid	and	enhance	counting.	Any	brown-stained	endothelial	cell	or	endothelial-cell	
cluster	that	was	clearly	separated	from	adjacent	microvessel,	tumor	cells,	and	other	
connective-tissue	elements	was	considered	a	single,	countable	microvessel	(Weidner	et	
al.,	1991).	Branching	vessel	structures	were	counted	as	a	single	vessel	(Sener	et	al.,	
2016).	Vascularity	was	not	considered	in	necrotic	areas	of	the	tumor.			
	
The	Weidner	approach	is	the	most	widely	used	and	quoted	method	for	quantification	of	
microvessel	density	(Goddard	et	al.,	2001;	Uzzan	et	al.,	2004).	The	quantification	of	
microvessels	in	vascular	hot	spots	is	thought	to	correlate	best	with	the	clinical	outcome	
due	to	its	relationship	with	haematogenous	spread	(Goddard	et	al.,	2001).	The	vascular	
hot	spots	in	the	tumor	periphery	were	chosen	as	these	areas	are	composed	of	typical	
capillaries	with	endothelial	cells,	derived	from	pre-existing	vessels	(Nico	et	al.,	2008).	
The	central	areas	of	the	tumor	are	composed	of	tube-like	endothelial	structures	and	
pseudo-vascular	channels	lined	by	tumor	cells,	not	endothelial	cells	(Nico	et	al.,	2008).	
	
5.1.7	Picrosirius	red	staining	
Picrosirius	red	staining	is	a	common	and	well-described	method	for	visualization	of	
collagen	in	tissue	sections	(Vogel	et	al.,	2015).	Sirius	red	is	an	elongated	molecule	
containing	six	salt-forming	sulfonic	groups,	which	reacts	with	the	basic	amino	groups	of	
lysine	and	hydroxylysine,	and	the	guanidine	group	of	arginine,	all	of	which	are	found	in	
collagens	(Bhutda	et	al.,	2017).	Thus,	picrosirius	red	binds	to	a	wide	variety	of	
molecules,	not	just	collagens	(Rittié,	2017,	pp.	395-407).	However,	the	parallel	
orientation	of	the	picrosirius	red	molecules	along	collagen	fibrils	greatly	enhances	the	
natural	birefringence	of	this	dye,	creating	a	complex	that	is	much	more	birefringent	than	
the	non-specific	complexes	between	picrosirius	red	and	other	proteins.	To	this	effect,	
picrosirius	red-bound	fibrillar	collagens	appear	bright	and	red	under	polarized	light,	
while	the	rest	of	the	tissue	remains	dark	(Vogel	et	al.,	2015;	Rittié,	2017,	pp.	395-407).	
	
The	software	ImageJ	was	used	to	identify	the	amount	of	pixels	positive	for	picrosirius	
red	staining.	The	threshold	values	were	adjusted	for	each	individual	image	to	adjust	for	
differences	in	intensity	and	background.	The	adjustment	of	threshold	values	may	vary	
from	person	to	person	and	thus	affect	the	quantification.	To	reduce	this	error	source	to	a	
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minimum,	the	same	person	conducted	the	threshold	adjustment	and	quantification	of	all	
images.			
	
5.2	Discussion	of	results	
	
5.2.1	Tumor	growth	
The	present	study	showed	no	significant	reduction	in	growth	of	the	mammary	E0771	
tumors	in	any	groups,	when	compared	to	the	WT	control	group.	However,	there	is	a	
trend	towards	a	slight	reduction	in	tumor	growth	in	both	of	the	integrin	α11-deficient	
groups,	KO	control	and	KO	Gleevec.	This	trend	was	more	pronounced	in	the	KO	control	
group,	which	also	demonstrated	a	significantly	reduction	tumor	growth	compared	to	the	
WT	Gleevec	group.		
	
Similar	to	these	results,	Reigstad	and	colleagues	found	that	integrin	α11-deficiency	did	
not	affect	the	growth	of	murine	TNBC	cell	line	4T1	in	vivo	(Reigstad	et	al.,	2016).	
However,	the	same	study	also	showed	that	integrin	α11-deficiency	significantly	
supressed	tumor	growth	in	the	prostate	cancer	cell	line	RM11.	In	addition,	a	recent	in	
vivo	study	by	Navab	and	colleagues	(Navab	et	al.,	2016)	demonstrated	that	integrin	α11-
deficiency	significantly	reduced	tumor	growth	in	non-small	cell	lung	carcinoma.	
Furthermore,	a	recent	in	vivo	study	in	our	group	(Hilde	Smeland,	unpublished	data)	has	
demonstrated	that	integrin	α11-deficiency	significantly	reduces	tumor	growth	in	the	
TNBC	cell	line	MDA-MB-231.	The	same	study	also	found	a	trend	towards	reduced	
growth	in	the	TNBC	cell	line	MDA-MB-468	(p=0.0568).					
	
Furthermore,	using	a	3D-heterospheroid	model	composed	of	mouse	embryonic	
fibroblasts	(α11	WT	and	α11-KO)	and	A549	lung	carcinoma	cells,	Lu	and	colleagues	(Lu	
et	al.,	2014)	found	that	integrin	α11-deficiency	resulted	in	significantly	larger	tumors.	
However,	the	α11-deficient	A549	spheroids	were	less	compact	then	the	controls,	with	
significantly	reduced	tumor	cell	proliferation.			
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In	the	present	study,	the	growth	of	the	E0771	tumors	was	not	significantly	affected	by	
Gleevec,	neither	the	WT	nor	the	α11-deficient	Gleevec	group	was	found	to	reduce	the	
tumor	growth	significantly.				
	
In	accordance	with	these	results,	no	significant	in	vivo	effect	on	tumor	growth	has	been	
reported	for	Gleevec	in	the	KAT-4	colonic	carcinoma	model	(Pietras	et	al.,	2002)	and	in	
L3.6pl	human	pancreatic	adenocarcinoma	(Hwang	et	al.,	2003).		
	
However,	Gleevec	has	been	reported	to	exert	a	significant	inhibitory	effect	on	the	
proliferation	of	breast	cancer	cells	in	vitro	(Roussidis	et	al.,	2004;	Malavaki	et	al.,	2013;	
Kadivar	et	al.,	2017).	In	addition,	Blanchard	and	colleagues	(Blanchard	et	al.,	2014)	
demonstrated	that	Gleevec	significantly	reduce	the	growth	of	the	TNBC	cell	line	MDA-
MB-231	in	vivo.	In	contrast	to	these	findings,	several	in	vivo	studies	have	reported	that	
Gleevec	enhanced	the	growth	rate	in	the	TNBC	cell	lines	MA-11	(Rappa	et	al.,	2011)	and	
4T1	(Samoszuk	and	Corwin,	2003).		
	
Taken	together,	these	findings	suggesting	that	the	effect	of	both	integrin	α11-deficiency	
and	Gleevec	might	be	dependent	on	inter-tumoral	differences	and/or	differences	in	the	
specific	tumor	microenvironments.	In	addition,	this	study	had	a	short	time	frame	(four	
days),	it	is	therefore	plausible	that	larger,	and	possibly	significant,	differences	in	tumor	
growth	might	have	been	found	if	the	time	frame	was	increased.			
	
	
5.2.2	Tumor	interstitial	fluid	pressure	
Elevated	interstitial	fluid	pressure,	which	is	frequently	observed	in	solid	tumors,	is	a	
result	of	increased	vascular	perfusion,	impaired	lymphatic	drainage,	high	ECM	density,	
and	integrin-mediated	contraction	of	interstitial	matrix	by	stromal	fibroblasts	(Heldin	et	
al.,	2004;	Stylianopoulos	et	al.,	2018).	High	vessel	permeability	increases	the	outflow	of	
water	and	solutes	into	the	interstitium,	whereas	impaired	or	non-functional	lymphatic	
vessels	cause	a	build-up	of	interstitial	fluid	due	to	ineffective	drainage.	This	is	further	
augmented	by	a	dense	and	contracted	ECM,	which	resists	the	percolation	of	interstitial	
fluid	(Stylianopoulos	et	al.,	2018).	High	IFP	decreases	the	transcapillary	transport	in	
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tumors,	and	thus	impedes	the	uptake	and	distribution	of	anti-cancer	therapeutics	
(Heldin	et	al.,	2004).		
	
In	the	present	study	we	found	that	integrin	α11-deficiency	significantly	lowers	the	
tumor	IFP,	demonstrated	by	significant	reductions	in	both	of	the	integrin	α11-deficient	
groups	compared	to	the	WT	control	group.	In	accordance	with	these	findings,	our	group	
has	recently	demonstrated	that	integrin	α11-deficiency	significantly	lowers	the	tumor	
IFP	in	the	TNBC	cell	lines	MDA-MB-231	and	MDA-MB-468	in	vivo	(Hilde	Smeland,	
unpublished	data).	In	addition,	integrin	α11β1	has	been	demonstrated	as	a	key	operator	
in	the	maintenance	of	homeostatic	IFP	in	the	dermis	in	vivo	(Svendsen	et	al.,	2009;	Lidén	
et	al.,	2018).	Furthermore,	using	the	previously	described	integrin	α11-deficient	A549	
heterospheroid	model,	Lu	and	colleagues	(Lu	et	al.,	2014)	demonstrated	that	α11-
deficiency	significantly	reduced	the	IFP	in	vitro.	Taken	together,	these	findings	suggest	
that	integrin	α11β1	acts	as	a	pressure	regulator	in	solid	tumors.		
	
The	mechanism	in	which	integrin	α11β1	influence	the	IFP	is	not	completely	elucidated.	
However,	integrin	α11β1	has	been	reported	as	the	major	collagen-receptor	on	
fibroblasts,	regulated	by	mechanical	strain	in	a	transforming	growth	factor-β	(TGF-β)-
dependent	manner	(Carracedo	et	al.,	2010;	Schnittert	et	al.,	2018).	Integrin	α11β1	is	
involved	in	the	regulation	of	myofibroblast	differentiation,	and	is	thus	central	to	the	
tumor	desmoplasia	and	ECM	contraction	(Carracedo	et	al.,	2010).	The	desmoplastic	
response	results	in	a	stiffer	and	contracted	collagen	network	which	might	be	more	
restrictive	of	changes	in	the	interstitial	volume	and	pose	an	obstacle	for	the	percolation	
of	interstitial	fluid	(Heldin	et	al.,	2004;	Stylianopoulos	et	al.,	2018).	It	is	therefore	
plausible	that	α11-deficiency	could	impede	the	effects	of	myofibroblasts	and	thereby	
reduce	both	the	IFP	and	collagen	density	in	the	tumors	(see	section	5.2.4).			
	
Treatment	with	the	PDGFR-inhibitor	Gleevec	also	resulted	in	significant	reduction	of	the	
IFP	in	the	WT	Gleevec	group.	However,	no	synergistic	or	additive	effect	was	observed	by	
Gleevec	treatment	in	the	α11-deficient	KO	Gleevec	group.	In	accordance	with	these	
results,	several	in	vivo	studies	has	demonstrated	that	Gleevec	significantly	reduce	the	
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IFP	in	the	colonic	carcinoma	models	CT26	(Burmakin	et	al.,	2017)	and	KAT-4	(Pietras	et	
al.,	2002;	Kłosowska-Wardȩga	et	al.,	2009;	Burmakin	et	al.,	2017).		
	
The	mechanism	in	which	Gleevec	reduce	the	IFP	is	still	elusive.	However,	in	an	in	vivo	
study	by	Olsson	at	al.,	(Olsson	et	al.,	2016)	on	colorectal	KAT-4/HT-29	experimental	
carcinomas,	they	found	that	Gleevec	treatment	decreased	the	diameter	of	the	collagen	
fibrils,	resulting	in	a	looser	and	more	flexible	collagen	network.	This	disturbance	in	the	
collagen	ultrastructure	allows	expansion	of	the	interstitial	fluid	volume	and	a	
subsequent	reduction	in	the	IFP.	These	findings	are	supportive	of	our	results.	We	found	
that	Gleevec	decreased	the	IFP,	however	the	collagen	density	in	the	E0771	tumor	model	
was	unaffected	(see	section	5.2.4).	Indicating	that	other	factors	are	involved.		
	
	
5.2.3	Tumor	vasculature	
Angiogenesis	is	stimulated	growth	of	new	blood	vessels	from	existing	vessels,	a	process	
that	is	essential	for	the	progression	of	cancer	(Goddard	et	al.,	2001).	Indeed,	sustained	
angiogenesis	is	one	of	the	hallmarks	of	cancer	and	a	requirement	for	tumor	growth	
beyond	the	initial	avascular	phase	(Hanahan	and	Weinberg,	2000;	Bamias	and	
Dimopoulos,	2003).	A	commonly	used	surrogate	marker	of	angiogenesis	is	the	
microvessel	density	(MVD),	i.e.	the	number	of	vessels	counted	in	a	given	area	of	tissue	
(Goddard	et	al.,	2001).	In	a	meta-analysis	conducted	by	Uzzan	and	colleagues	(Uzzan	et	
al.,	2004)	high	MVD	was	found	as	a	prognostic	factor,	significantly	predicting	poorer	
survival	in	women	with	breast	cancer.			
	
In	this	thesis,	we	found	that	integrin	α11-deficiency	significantly	reduced	the	MVD	in	
both	α11-deficient	groups	compared	to	the	WT	control	group.	Interestingly,	the	MVD	
was	significantly	lower	in	the	α11-deficient	control	group	compared	to	the	α11-
deficient	Gleevec	group.	This	suggests	that	inhibition	of	PDGFR	signalling	partly	repress	
the	anti-angiogenic	effect	of	α11-deficiency	in	the	E0771	tumors.	The	anti-angiogenic	
effect	of	integrin	α11-deficiency	is	largely	unexplored,	thus	the	findings	in	this	study	
might	indicate	novel	roles	for	integrin	α11β1,	with	the	potential	for	medical	
applications.			
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As	mentioned,	the	role	of	integrin	α11β1	in	angiogenesis	is	currently	unknown.	
However,	integrin	α11β1	is	involved	in	myofibroblast	differentiation,	as	discussed	in	
section	5.2.2	and	5.2.4	(Schnittert	et	al.,	2018).	Stromal	myofibroblasts	are	important	
contributors	to	tumor	angiogenesis	and	produce	a	plethora	of	pro-angiogenic	growth	
factors,	including	VEGF,	TGFβ	and	PDGFs	(Vong	and	Kalluri,	2011).	Furthermore,	
stromal	myofibroblasts	are	a	key	source	of	matrix	remodelling	proteins,	which	facilitate	
and	coordinate	growing	tumor	vasculature	(Senger	and	Davis,	2011;	Vong	and	Kalluri,	
2011).	Thus,	the	absence	of	integrin	α11β1	might	impair	the	multi-faceted	roles	of	
myofibroblasts	in	tumor	progression	and	angiogenesis.			
	
In	the	present	study,	the	MVD	in	both	Gleevec	groups	was	significantly	reduced	
compared	to	the	WT	control	group.	In	accordance	with	these	findings,	Gleevec	has	been	
shown	to	significantly	reduce	the	MVD	in	the	L3.6pl	pancreatic	adenocarcinoma	model	
(Hwang	et	al.,	2003),	A549	non-small	cell	lung	cancer	models	(Vlahovic	et	al.,	2006,	
2007),	and	in	the	KAT-4	colonic	carcinoma	(Kłosowska-Wardȩga	et	al.,	2009)	in	vivo.		
	
The	PDGF/PDGFR	signalling	axis	has	been	demonstrated	as	an	important	contributor	in	
tumor-associated	angiogenesis,	and	overexpression	of	PDGFs	correlates	with	increased	
MVD	and	poor	survival	in	a	range	of	human	cancers	(Raica	and	Cimpean,	2010).	PDGFs	
stimulate	endothelial	cell	proliferation	and	the	secretion	of	vascular	endothelial	growth	
factor	(VEGF),	a	well-described	and	potent	angiogenic	inducer	(Bamias	and	Dimopoulos,	
2003;	Raica	and	Cimpean,	2010).	Particularly,	the	PDGF-B/PDGFRβ	signalling	pathway	
has	been	shown	to	play	a	critical	role	in	the	establishment	of	functional	blood	vessels	
through	the	recruitment	and	stabilization	of	perivascular	cells	(Raica	and	Cimpean,	
2010).	Importantly,	the	coating	of	perivascular	cells,	such	as	pericytes,	on	the	
endothelial	cells	prevents	excessive	angiogenic	sprouting	(Cao,	2013).	However,	PDGF-
BB	is	a	potent	chemotactic	factor	for	pericytes,	thus	high	levels	of	tumor	cell-derived	
PDGF-BB	may	attract	pericytes	away	from	blood	vessels	resulting	in	decreased	pericyte	
coverage	and	induction	of	angiogenesis	(Hosaka	et	al.,	2013).	This	is	in	accordance	with	
the	results	found	in	our	study.		
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5.2.4	Tumor	collagen	density	
Human	tumors	are	stiffer	than	normal	tissue,	and	this	alteration	of	mechanical	
properties	in	tumors	reflects	increased	IFP	and	compressive	loading,	ECM	stiffening,	and	
elevated	cell	contractility	and	rheology	(Acerbi	et	al.,	2015).	A	major	contributor	to	
tumor	mechanics	is	the	desmoplastic	response,	which	is	accompanied	by	the	excessive	
accumulation	of	fibrillar	collagens,	increased	remodelling	and	cross-linking	(Acerbi	et	
al.,	2015;	Kalli	and	Stylianopoulos,	2018).	Desmoplasia	and	ECM	stiffening	is	
characterizing	features	in	many	tumor	type,	and	usually	promotes	tumor	progression	
(Kalli	and	Stylianopoulos,	2018).	In	breast	cancer,	tissue	stiffness	predicts	poor	relapse-
free	survival,	reduced	therapy	response	and	shorter	overall	survival	(Insua-Rodríguez	
and	Oskarsson,	2016).	
	
In	a	comprehensive	biophysical	and	histological	analysis	of	human	breast	tissue,	Acerbi	
and	colleagues	(Acerbi	et	al.,	2015)	demonstrated	that	breast	cancer	transformation	was	
accompanied	by	progressive	deposition	and	remodelling	of	type	I	collagen	and	
increased	mechanosignalling.	The	same	study	also	demonstrated	that	the	more	
aggressive	breast	cancer	subtypes,	such	as	TNBC,	was	stiffer,	more	heterogeneous,	and	
contained	cells	with	the	higher	mechanosignalling	compared	to	less	aggressive	
subtypes.		
	
In	the	present	study	we	found	that	the	tumor	collagen	density	was	significantly	lower	in	
the	α11-deficient	groups	compared	to	both	the	WT	control	and	the	WT	Gleevec	group,	
indicating	that	integrin	α11-deficiency	impede	the	excessive	accumulation	of	collagens.	
This	is	possibly	a	result	of	the	involvement	of	integrin	α11β1	in	myofibroblast	
differentiation	and	desmoplasia.		
	
In	contrast	to	these	results,	Reigstad	and	colleagues	(Reigstad	et	al.,	2016)	found	that	
integrin	α11-deficiency	did	not	affect	the	tumor	collagen	density	in	the	TNBC	cell	line	
4T1	or	the	prostate	cancer	cell	line	RM11	in	vivo.	Suggesting	that	the	effect	of	integrin	
α11β1	on	the	collagen	density	may	vary	between	different	tumor	types.					
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The	receptor	tyrosine	kinase	inhibitor	Gleevec	did	not	affect	the	collagen	density.	The	
WT	Gleevec	group	exhibited	significantly	higher	collagen	density	compared	to	the	α11-
deficient	groups.	Interestingly,	the	α11-deficient	KO	Gleevec	group	had	significantly	
lower	collagen	density	compared	to	the	WT	Gleevec	group,	suggesting	that	the	reduction	
in	collagen	density	was	solely	contributed	by	integrin	α11-deficiency.		
	
Consistent	with	this,	a	previously	described	(section	5.2.2)	study	by	Olsson	and	
colleagues	(Olsson	et	al.,	2016)	reported	that	Gleevec	did	not	affect	the	total	collagen	
amount	in	colorectal	KAT-4/HT-29	experimental	carcinomas.	Instead,	Gleevec	
treatment	decreased	the	diameter	of	the	collagen	fibrils,	resulting	in	a	looser	and	more	
flexible	collagen	network.		
	
	
5.3	Conclusion	
The	main	goal	of	this	thesis	was	to	evaluate	the	in	vivo	effect	of	integrin	α11-deficiency	
and	PDGF-inhibition	in	the	murine	E0771	triple-negative	breast	cancer	model.	This	was	
addressed	through	two	specific	aims:		
	
1. Evaluate	the	in	vivo	effect	of	integrin	α11-deficiency	on	tumor	growth,	
interstitial	fluid	pressure,	angiogenesis,	and	collagen	density	in	the	murine	
E0771	TNBC	model.	
		
Integrin	α11-deficiency	did	not	affect	the	tumor	growth	in	the	murine	triple-negative	
breast	cancer	E0771	animal	model	compared	to	the	WT	control	group.	However,	the	
interstitial	fluid	pressure,	microvessel	density,	and	collagen	density	was	significantly	
reduced	in	both	of	the	integrin	α11-deficient	groups.	The	reduction	in	interstitial	fluid	
pressure	might	be	caused	by	reduced	collagen	density	and	lower	microvessel	density.	
Interestingly,	the	microvessel	density	was	significantly	higher	in	the	KO	Gleevec	group	
compared	to	the	KO	control	group,	indicating	that	α11-deficiency	is	more	efficient	in	
reducing	the	microvessel	density	in	absence	of	Gleevec.	No	synergistic	or	additive	effect	
was	observed	in	response	to	inhibition	of	PDGF	signalling	in	the	α11-deficient	groups.		
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2. Evaluate	the	in	vivo	effect	of	PDGF	inhibition	on	tumor	growth,	interstitial	
fluid	pressure,	angiogenesis,	and	collagen	density	in	the	murine	E0771	
TNBC	model.		
	
The	PDGF-inhibitor	Gleevec	did	not	affect	the	tumor	growth	or	the	collagen	density	in	
the	murine	E0771	triple-negative	breast	cancer	model	compared	to	the	WT	control	
group.	The	interstitial	fluid	pressure	and	microvessel	density	was	significantly	reduced	
in	both	Gleevec	groups	compared	to	the	WT	control	group.	However,	the	WT	Gleevec	
group	had	significantly	higher	growth,	microvessel	density,	and	collagen	density	
compared	to	the	integrin	α11-deficient	KO	control	group.	Indicating	that	PDGF/PDGFR	
signalling	is	important	in	the	regulation	of	pressure	homeostasis	and	angiogenesis	in	
this	tumor	model.		
	
Taken	together,	this	study	indicates	that	integrin	α11β1	promotes	a	pro-tumorigenic	
microenvironment.	To	that	effect,	integrin	α11β1	might	represent	a	novel	ECM	target	
for	medical	applications,	especially	in	adjuvant	settings	to	increase	uptake	and	
distribution	of	systemically	administered	anti-cancer	drugs.	However,	since	the	
functional	roles	of	integrin	α11β1	is	not	fully	uncovered,	further	investigations	are	
needed	to	verify	these	effects	in	a	wider	range	of	tumor	types.	
	
The	present	study	also	indicated	that	inhibition	of	PDGF/PDGFR	signalling	by	Gleevec	
might	increase	therapeutic	efficiency	through	the	reduction	in	interstitial	fluid	pressure	
and	microvessel	density.	However,	further	investigations	are	needed	to	fully	elucidate	
the	mechanism	in	which	the	reduction	occurs.			
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6	Future	perspectives	
	
The	functional	roles	of	integrin	α11β1	in	the	tumor	microenvironment	are	still	largely	
unknown.	The	findings	presented	here	indicate	that	integrin	α11β1	is	an	important	
contributor	to	a	pro-tumorigenic	tumor	microenvironment	in	TNBC,	impacting	the	
interstitial	fluid	pressure,	microvessel	density	and	collagen	density.	Considering	the	
influence	these	factors	have	on	breast	cancer	progression,	integrin	α11β1	could	
potentially	represent	an	attractive	target	for	medical	applications,	especially	in	adjuvant	
settings	to	increase	the	efficiency	of	traditional	therapy	due	to	the	reduction	of	IFP.	
However,	the	findings	presented	here	should	be	further	investigated	to	see	if	they	are	
representative	for	a	wider	range	of	tumor	types.			
	
In	addition,	further	investigation	on	the	tumor	collagen	should	be	conducted	using	
transmission	electron	microscopy	(TEM)	to	obtain	a	wider	perspective	of	how	the	
collagen	fibril	diameter	and	organization	is	affected.	In	addition,	the	tumor	collagen	
scaffold	architecture	should	be	investigated	by	scanning	electron	microscopy	(SEM)	to	
evaluate	the	effects	on	the	tumor	collagen	network.		
	
Further	studies	should	also	investigate	the	mechanism	in	which	Gleevec	reduces	the	
tumor	IFP	and	MVD,	and	how	this	is	affected	by	different	microenvironments.		
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8	Appendix	A	
		
	
Genotyping	of	integrin	α11-deficient	mice	
	
	
Solutions:	
	
MGB	stock	solution:	
8400	µL	MilliQ	
1000	µL	10x	MGB	
		100	µL	Mercaptoethanol	
		500	µL	Triton	X-100	(diluted	1:10	in	MilliQ)	
	
Proteinase	K	(2	mg/mL):	
Dilute	proteinase	K	in	RNase	free	water	(2	mg/mL)	
	
PCR	stock	solution:	
Mix	stock	solution	in	an	Eppendorf	tube.	Use	RNase	free	pipets	and	work	on	ice.		
	
Solutions	 1x		 27x	
10	x	buffer-MgCl2	 2	µl	 54	µl	
dNTP	10	mM	 0,4	µl	 10,8	µl	
Ko-wt	fw	and	rew	 0,5+0,5	µl	 13,5+13,5	µl	
Lac	z1	and	lac	z2	 0,25+0,25	µl	 6,75+6,75	µl	
Polymerase	(5u/ml)	 0,1	µl	 2,7	µl	
H20		 14	µl	 378	µl	
DNA		 2µl	µl	 2	µl	
Totalt	 20	µl	 	
	
	
	
Purification:	
-Add	40	µL	MGB	stock	to	each	earpiece	and	heat	inactivate	at	95OC	for	5	min,	using	a	
heat	block	shaker.		
-Cool	PCR	tubes	on	ice	and	add	2	µl	proteinase	K	to	each	tube,	and	incubate	at	56OC	for	1	
hour,	using	a	heat	block	shaker.	
-Heat	inactivate	at	95OC	for	5	min,	using	a	heat	block	shaker.		
-Centrifuge	for	10	min.		
-Dilute	the	samples	1:5	in	buffer			
	
PCR:	
Mix	PCR	stock	solution	and	distribute	18	µl	to	each	PCR	tube.	Add	2	µl	purified	DNA.		
Run	PCR	program	GT-KOWT.	
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Separation:	
-Dissolve	1	g	agarose	in	50	µl	TAE	buffer	(1	gel),	boil	in	microwave	until	completely	
dissolved.		
-Add	3	µl	GelRed	TM	Nucleic	acid	gel	stain	and	swirl	the	flask	until	completely	dissolved.	
-Pour	gel	in	rack	at	leave	it	for	20-30	min.	
-Add	buffer	to	separation	rack.		
	
-Add	4	µl	loading	dye	to	each	sample.	
-Load	10	µl	sample	in	wells.	
-Load	5	µl	ladder	
-run	gel	at	90	V	for	20-30	min	
-	Develop	image		
	
